Lipotoxicity Disrupts Erythrocyte Function: A Perspective.

Q2 Medicine Cardiovascular and Hematological Disorders - Drug Targets Pub Date : 2021-01-01 DOI:10.2174/1871529X21666210719125728

Charalampos Papadopoulos, Ioannis Tentes, Konstantinos Anagnostopoulos

{"title":"Lipotoxicity Disrupts Erythrocyte Function: A Perspective.","authors":"Charalampos Papadopoulos, Ioannis Tentes, Konstantinos Anagnostopoulos","doi":"10.2174/1871529X21666210719125728","DOIUrl":null,"url":null,"abstract":"Background: Lipid accumulation in the liver, skeletal and cardiac muscle, kidneys and pancreas causes cell dysfunction, death and inflammation, a biological phenomenon named lipotoxicity. Erythrocytes participate in the transport of lipids in the circulation, and their lipidome is determined by exchange with blood components.Objective: The objective of this study is to summarize the current knowledge regarding the effect of toxic lipid accumulation in erythrocytes.Results: Erythrocyte lipidome is altered in lipotoxic diseases, such as fatty liver disease, heart failure and diabetes. In addition, ceramide, lysophosphatidylcholine, lysophosphatidic acid, palmitic acid and free cholesterol induce erythrocyte malfunction.Conclusion: Erythrocytes are an additional cell target of lipotoxicity. Further exploration of the implicated molecular mechanisms could lead to novel therapeutic targets for cardiometabolic and hematological diseases.","PeriodicalId":9543,"journal":{"name":"Cardiovascular and Hematological Disorders - Drug Targets","volume":"21 2","pages":"91-94"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular and Hematological Disorders - Drug Targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871529X21666210719125728","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

Abstract

Background: Lipid accumulation in the liver, skeletal and cardiac muscle, kidneys and pancreas causes cell dysfunction, death and inflammation, a biological phenomenon named lipotoxicity. Erythrocytes participate in the transport of lipids in the circulation, and their lipidome is determined by exchange with blood components.

Objective: The objective of this study is to summarize the current knowledge regarding the effect of toxic lipid accumulation in erythrocytes.

Results: Erythrocyte lipidome is altered in lipotoxic diseases, such as fatty liver disease, heart failure and diabetes. In addition, ceramide, lysophosphatidylcholine, lysophosphatidic acid, palmitic acid and free cholesterol induce erythrocyte malfunction.

Conclusion: Erythrocytes are an additional cell target of lipotoxicity. Further exploration of the implicated molecular mechanisms could lead to novel therapeutic targets for cardiometabolic and hematological diseases.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

脂肪毒性破坏红细胞功能:一个视角。

背景:脂质在肝脏、骨骼肌和心肌、肾脏和胰腺的积累会导致细胞功能障碍、死亡和炎症，这是一种被称为脂质毒性的生物学现象。红细胞参与循环中的脂质运输，其脂质组由与血液成分的交换决定。目的:本研究的目的是总结目前关于红细胞中毒性脂质积累作用的知识。结果:脂毒性疾病，如脂肪肝、心力衰竭和糖尿病，红细胞脂质组发生改变。此外，神经酰胺、溶血磷脂酰胆碱、溶血磷脂酸、棕榈酸和游离胆固醇可引起红细胞功能障碍。结论:红细胞是脂毒性的另一个靶细胞。对相关分子机制的进一步探索可能会导致心脏代谢和血液疾病的新治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular and Hematological Disorders - Drug Targets Medicine-Cardiology and Cardiovascular Medicine

CiteScore

1.90

自引率

0.00%

发文量

期刊介绍： Cardiovascular & Hematological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow.